PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

Seizing the Undiagnosed Patients Market Opportunity

Complicated vs Complex Challenges in Pharma

Tips for Success from a Big Pharma Leader

Industry Trends
Pharm Exec's Top 50 Companies 2017
Pharm Exec's 17th annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.
... /Read more/
Advertisement
The Changing Market for Drugs to Treat Orphan Diseases
Live Webinar: Tuesday, July 18 at 10am EDT
Register now
Pricing
Congress Struggles to Address Drug Prices
Congressional measures lack the support to move forward, writes Jill Wechsler.
... /Read more/
Advertisement
Through the Patient's Eyes - Needs, Behaviors and the Science Behind it All
On Demand
Learn more
Regulatory
The Quest for Meaningful Pharma-Patient Dialogue
With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.
... /Read more/
Advertisement
Emerging Biopharma and Rare Disease: Finding a Needle in a Haystack
Data-driven Patient Recruitment Solutions
On Demand
Learn more
Industry Trends
Navigating Through Disruption: A Pharma 50 View
Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.
... /Read more/
Advertisement
Talking the Patients' Language – the importance of effective, patient-centered engagement
On Demand
Learn more
Recruitment
Talent That Takes You into the Future
There's no shortage of talent, expertise, and passion in the biopharma industry. It's time for that talent to shine, writes Lisa Henderson.
... /Read more/
Advertisement
THE IMPORTANCE OF STAKEHOLDER RESEARCH IN RARE DISEASE DRUG DEVELOPMENT
The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications. With this increase Rare Disease Drug Development and broadening class of products, including some that target the same mutation or molecular defect, sponsors face new and significant market access challenges in securing reimbursement. Sponsored by Covance.
Learn more
Calendar
 
/ Bio/Pharma Strategic Portfolio Management Summit 8/8 /
 
/ 11th Annual Forum on Transparency & Aggregate Spend 8/14-8/16 /
 
/ Patient Journey Mapping: From Diagnosis to Treatment 8/15-8/16 /
 
/ Reimbursement and Access 8/15-8/16 /
 
Advertisement
Coming to terms with Patient Centricity
On Demand
Learn more
 
Advertisement
Launch Excellence V: Surviving and thriving in a specialized world
On Demand
Learn more
update my profile / advertise with us / print & digital subscribe / visit pharmexec.com